Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H44O7 |
| Molecular Weight | 480.6341 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(O)CC[C@@H](O)[C@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C
InChI
InChIKey=NKDFYOWSKOHCCO-YPVLXUMRSA-N
InChI=1S/C27H44O7/c1-23(2,32)9-8-22(31)26(5,33)21-7-11-27(34)16-12-18(28)17-13-19(29)20(30)14-24(17,3)15(16)6-10-25(21,27)4/h12,15,17,19-22,29-34H,6-11,13-14H2,1-5H3/t15-,17-,19+,20-,21-,22+,24+,25+,26+,27+/m0/s1
| Molecular Formula | C27H44O7 |
| Molecular Weight | 480.6341 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
20-Hydroxyecdysone is a naturally occurring ecdysteroid hormone, which is marketed as dietary supplements that can increase strength and muscle mass during resistance training, particularly bodybuilding. It was found, that 20-hydroxyecdysone did not affect body composition or training adaptations nor did they influence the anabolic/catabolic hormone status or general markers of catabolism in resistance-trained males. Because is known, that ecdysteroids have been shown to prevent various changes in mammalian tissues after female sex hormone deprivation. 20-Hydroxyecdysone also was investigated on these properties. It was found in rats, that 20-Hydroxyecdysone had a beneficial effect on reducing blood pressure and consequently preventing dilated cardiac hypertrophy. Some in vitro experiments showed, that 20-hydroxyecdysone had effects on lymphocytes and neutrophils, and may act as an immunomodulator.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
141 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
317 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
399 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
710 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
1400 mg single, oral dose: 1400 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
346 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 1 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
388 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 1 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
453 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
506 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
524 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
450 mg 2 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
560 ng/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
450 mg 2 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
819 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1927 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2589 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4097 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
1400 mg single, oral dose: 1400 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2141 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 1 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2389 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 1 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2234 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2768 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2429 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
450 mg 2 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3203 ng × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
450 mg 2 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.4 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.26 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg single, oral dose: 350 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.85 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
700 mg single, oral dose: 700 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.84 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
1400 mg single, oral dose: 1400 mg route of administration: Oral experiment type: SINGLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.39 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 1 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.39 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 1 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.06 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
350 mg 2 times / day multiple, oral dose: 350 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
3.72 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
450 mg 2 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
|
2.81 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/37057316/ |
450 mg 2 times / day multiple, oral dose: 450 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
20-HYDROXYECDYSONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Steroid-triggered programmed cell death of a motoneuron is autophagic and involves structural changes in mitochondria. | 2003-03-17 |
|
| The effects of serotonin and ecdysone on primary sensory neurons in crayfish. | 2003-02-15 |
|
| 11beta-Hydroxysteroid dehydrogenase type 1: tissue-specific expression and reductive metabolism of some anti-insect agent azole analogues of metyrapone. | 2003-02-01 |
|
| Effects of 20-hydroxyecdysone and serotonin on neurite growth and survival rate of antennal lobe neurons in pupal stage of the silk moth Bombyx mori in vitro. | 2003-02 |
|
| Binding mode of ecdysone agonists to the receptor: comparative modeling and docking studies. | 2003-02 |
|
| Synthesis and insecticidal activity of benzoheterocyclic analogues of N'-benzoyl-N-(tert-butyl)benzohydrazide: Part 1. Design of benzoheterocyclic analogues. | 2003-01 |
|
| Entomogenous fungus Nomuraea rileyi inhibits host insect molting by C22-oxidizing inactivation of hemolymph ecdysteroids. | 2003-01 |
|
| Molecular cloning and expression analysis of ultraspiracle (USP) from the rice stem borer Chilo suppressalis. | 2003-01 |
|
| Antioxidative and free radical scavenging effects of ecdysteroids from Serratula strangulata. | 2002-12 |
|
| Interactions between Spinacia oleracea and Bradysia impatiens: a role for phytoecdysteroids. | 2002-12 |
|
| A molt-associated chitinase cDNA from the spruce budworm, Choristoneura fumiferana. | 2002-12 |
|
| The orphan nuclear receptors BmE75A and BmE75C of the silkmoth Bombyx mori: hornmonal control and ovarian expression. | 2002-12 |
|
| Developmental profiles and ecdysone regulation of the mRNAs for two ecdysone receptor isoforms in the Mediterranean fruit fly Ceratitis capitata. | 2002-12 |
|
| The BmE75 nuclear receptors function as dominant repressors of the nuclear receptor BmHR3A. | 2002-11-01 |
|
| Molecular characterization of the insect immune protein hemolin and its high induction during embryonic diapause in the gypsy moth, Lymantria dispar. | 2002-11 |
|
| Ecdysteroids of Vitex scabra stem bark. | 2002-11 |
|
| Developmental toxicity of testosterone in the crustacean Daphnia magna involves anti-ecdysteroidal activity. | 2002-11 |
|
| A possible role of 20-hydroxyecdysone in embryonic development of the silkworm Bombyx mori. | 2002-11 |
|
| Differential expression and regulation by 20-hydroxyecdysone of mosquito ecdysteroid receptor isoforms A and B. | 2002-10-31 |
|
| Applying fenoxycarb at the penultimate instar triggers an additional ecdysteroid surge and induces perfect extra larval molting in the silkworm. | 2002-10-01 |
|
| Steroid regulation of midgut cell death during Drosophila development. | 2002-10-01 |
|
| Ance, a Drosophila angiotensin-converting enzyme homologue, is expressed in imaginal cells during metamorphosis and is regulated by the steroid, 20-hydroxyecdysone. | 2002-10-01 |
|
| A novel putative insect chitinase with multiple catalytic domains: hormonal regulation during metamorphosis. | 2002-09-15 |
|
| Ecdysteroids from a Zoanthus sp. | 2002-08 |
|
| Production of the baculovirus-expressed dengue virus glycoprotein NS1 can be improved dramatically with optimised regimes for fed-batch cultures and the addition of the insect moulting hormone, 20-Hydroxyecdysone. | 2002-08 |
|
| Crystal structures of ecdysteroids: the role of solvent molecules in hydrogen bonding and isostructurality. | 2002-08 |
|
| A protein from the cabbage looper, Trichoplusia ni, regulated by a bacterial infection is homologous to 3-dehydroecdysone 3beta-reductase. | 2002-08 |
|
| Induction of the early-late Ddc gene during Drosophila metamorphosis by the ecdysone receptor. | 2002-06 |
|
| Molecular cloning and induction of nuclear receptors from insect cell lines. | 2002-06 |
|
| Hormonal control of GTP cyclohydrolase I gene expression and enzyme activity during color pattern development in wings of Precis coenia. | 2002-06 |
|
| 3-Deoxy-1beta,20-dihydroxyecdysone from the leaves of Diploclisia glaucescens. | 2002-06 |
|
| [Vitamin D3 and 20-hydroxyecdysone -- inhibitors of free radical lipid oxidation during D-hypervitaminosis]. | 2002-05-31 |
|
| Reproductive and developmental effects of endocrine disrupters in invertebrates: in vitro and in vivo approaches. | 2002-05-10 |
|
| Ecdysone triggers the expression of Golgi genes in Drosophila imaginal discs via broad-complex. | 2002-05-01 |
|
| Intensity of larval diapause in the bamboo borer, Omphisa fuscidentalis. | 2002-05 |
|
| Existence of ionotropic glutamate receptor subtypes in cultured rat retinal ganglion cells obtained by the magnetic cell sorter method and inhibitory effects of 20-hydroxyecdysone, a neurosteroid, on the glutamate response. | 2002-05 |
|
| Two isoforms of the early E74 gene, an Ets transcription factor homologue, are implicated in the ecdysteroid hierarchy governing vitellogenesis of the mosquito, Aedes aegypti. | 2002-04-25 |
|
| Ecdysteroids and oocyte development in the black fly Simulium vittatum. | 2002-04-24 |
|
| Diastereomeric ecdysteroids with a cyclic hemiacetal in the side chain produced by cytochrome P450 in hormonally resistant insect cells. | 2002-04-15 |
|
| Phytoecdysteroid levels and distribution during development in Limnanthes alba Hartw. ex Benth. (Limnanthaceae). | 2002-04-03 |
|
| The expression of the let-7 small regulatory RNA is controlled by ecdysone during metamorphosis in Drosophila melanogaster. | 2002-04-01 |
|
| Ultrastructural changes in the corpus allatum after azadirachtin and 20-hydroxyecdysone treatment in adult females of Labidura riparia (Dermaptera). | 2002-04 |
|
| Spatial patterns of ecdysteroid receptor activation during the onset of Drosophila metamorphosis. | 2002-04 |
|
| Expression of Manduca sexta V-ATPase genes mvB, mvG and mvd is regulated by ecdysteroids. | 2002-04 |
|
| DNA synthesis in the imaginal wing discs of the American bollworm Helicoverpa armigera (Hübner). | 2002-03 |
|
| Effects of insect hormones on hemagglutination activity in two members of the Culex pipiens complex. | 2002-01 |
|
| Metamodulation of the biogenic amines: second-order modulation by steroid hormones and amine cocktails. | 2002 |
|
| [Structural diversity of ecdysteroids of Lychnis flos-cuculi]. | 2001-08 |
|
| Comparative action of RH-0345 and pyriproxyfen on molting hormone production and protein analysis in mealworm pupae. | 2001 |
|
| RH-0345 restored partly the effects induced by KK-42 on reproductive events in mealworms. | 2001 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18500969
200 mg of 20-hydroxyecdysone for 8-weeks during training. At 0, 4, and 8-weeks, subjects donated fasting blood samples and completed comprehensive muscular strength, muscular endurance, anaerobic capacity, and body composition.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10398339
20-hydroxyecdysone (1 microM) was found to activate in vitro T-cell CD2 presentation, which is suppressed both in secondary immunodeficient persons and pharmacologically by increasing intracellular cAMP levels. In addition, 20-hydroxyecdysone (1 microM) was also revealed to modulate the fluoride-stimulated respiratory burst of human neutrophils in the same manner as water soluble antioxidants.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:14:33 GMT 2025
by
admin
on
Mon Mar 31 22:14:33 GMT 2025
|
| Record UNII |
779A7KPL0Y
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/18/2030
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
||
|
DSLD |
1581 (Number of products:12)
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
||
|
FDA ORPHAN DRUG |
639318
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16587
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
5459840
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
ecdysterone
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
DTXSID5040388
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
629484
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
100000178051
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
779A7KPL0Y
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
m4808
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
20-Hydroxyecdysone
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY | |||
|
5289-74-7
Created by
admin on Mon Mar 31 22:14:33 GMT 2025 , Edited by admin on Mon Mar 31 22:14:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|